As of Thursday close, Zimmer Biomet Holdings Inc.’s (NYSE:ZBH) stock was down -$2.51, moving down -2.09 percent to $117.80. The average number of shares traded per day over the past five days has been 1,528,600 shares. 1 time new highs have been achieved over the past 5 days, with a -$3.82 fall in that time frame. In the last twenty days, the average volume was 1,737,175, while in the previous 50 days, it was 1,590,766.
Since last month, ZBH stock rose 1.77%. Shares of the company fell to $113.99 on 08/24/23, the lowest level in the past month. A 52-week high of $149.25 was reached on 05/02/23 after having rallying from a 52-week low of $102.60. Since the beginning of this year, ZBH’s stock price has dropped by -7.61% or -$9.70, and marked a new high 10 times. However, the stock has declined by -21.07% since its 52-week high.
ZBH stock investors should be aware that Zimmer Biomet Holdings Inc. (ZBH) stock had its last reported insider trading activity 23 days ago on Aug 30. Kolli Sreelakshmi, the Director of the company, purchased of 1,000 shares for $120.37 on Aug 30. It resulted in a $120,370 investment by the insider. HAGEMANN ROBERT added 2,000 shares at an average price of $116.48 on Aug 28. The insider now owns 4,000 shares following the transaction. On Aug 25, Director MICHELSON MICHAEL W bought 1,300 shares at $115.50 apiece. The transaction was valued at $150,150.
Valuation Metrics
Right now, Zimmer Biomet Holdings Inc. (ZBH) has a P/E ratio of about 49.00. The stock’s beta is 1.03. Besides these, the trailing price-to-sales (P/S) ratio of 3.43, the price-to-book (PB) ratio of 1.99, and the price-to-cash flow ratio of 34.43 may also be considered.
The latest dividend of $0.24 per share was paid out, remained unchanged from last year’s $0.24. On Wednesday February 24 2016, a $0.02 dividend increase was announced.
Financial Health
In the three months ended June 29, Zimmer Biomet Holdings Inc.’s quick ratio stood at 0.90, while its current ratio was 2.00, showing that the company is not able to pay off its debt. According to company report, the long-term debt-to-equity ratio for the quarter ending June 29 was 0.42, and the total debt-to-equity ratio was 0.46. On the profitability front, the trailing twelve-month gross margin is 71.70% percent. In the year ended June 29, EBITDA margin amounted to 30.69%, whereas operating margins totaled 12.10%. Based on annual data, ZBH earned $4.92 billion in gross profit and brought in $6.94 billion in revenue.
A company’s management is another factor that investors consider when determining the profitability of an investment. In the past year, return on investment (ROI) was 3.30%. Return on equity (ROE) for the past 12 months was 4.10%.
In Zimmer Biomet Holdings Inc.’s quarter-end financial report for June 29, it reported total debt of $5.19 billion. According to the earnings report, the company had a higher net income in the recent quarter than it did in the previous quarter. ZBH’s revenue rose 4.7% to $1.83 billion during the quarter, while net income inched up to $1.87 billion. While analysts expected Zimmer Biomet Holdings Inc. to report $1.81 quarterly earnings, the actual figure was $1.82 per share, beating the consensus estimate by 0.60%. During the quarter, the company generated $567.2 million in EBITDA. The liabilities of Zimmer Biomet Holdings Inc. were 8.92 billion at the end of its most recent quarter ended June 29, and its total debt was $5.92 billion. The value of shareholders’ equity is $208.96 million.
Technical Picture
This quick technical analysis looks at Zimmer Biomet Holdings Inc.’s (ZBH) price momentum. With a historical volatility rate of 16.13%, the RSI 9-day stood at 36.07% on 21 September.
With respect to its five-day moving average, the current Zimmer Biomet Holdings Inc. price is down by -3.14% percent or -$3.82. At present, ZBH shares trade +2.57% above its 20-day simple moving average and -14.91% percent below its 100-day simple moving average. However, the stock is currently trading approximately -17.42% below its SMA50 and -4.20% below its SMA200.
Stochastic coefficient K was 38.38% and Stochastic coefficient D was 56.31%, while ATR was 2.25. Given the Stochastic reading of 4.78% for the 14-day period, the RSI (14) reading has been calculated as 38.30%. As of today, the MACD Oscillator reading stands at -1.11, while the 14-day reading stands at -0.83.
Analyst Ratings
BTIG Research upgraded its rating on Zimmer Biomet Holdings Inc. (NYSE: ZBH) to a Buy in a note to investors on August 28, 2023. The analysts firm previously had a Neutral rating on the stock.Zimmer Biomet Holdings Inc. (ZBH) has been rated Hold by analysts. According to 2 brokerage firms, ZBH is a sell, and 14 firms recommend it is a Hold. There are 1 analyst who say the stock is underweight. A total of 3 analysts rate Zimmer Biomet Holdings Inc. stock as buy, with 8 recommending it as overweight.
With a median target price of $150.25, the current consensus forecast for the stock is $120.00 – $172.00. Based on these forecasts, analysts predict Zimmer Biomet Holdings Inc. (ZBH) will achieve an average price target of $149.98.
